Nicholas B. Lydon
In 2011 Nicholas B. Lydon was named a Thomson Reuters Citation Laureate in Medicine with Brian J. Druker and Charles L. Sawyers for their development of imatinib and dasatinib, revolutionary, targeted treatments for chronic myeloid leukemia. Below are more details.
- Role: Founder, Granite Biopharma, LLC, Jackson Hole, WY USA; Co-founder and Director, AnaptysBio, San Diego, CA USA; and Co-founder and Director, Blueprint Medicines, Cambridge, MA USA